相似文献
1
Reply.
Clin Gastroenterol Hepatol. 2016 Jan;14(1):167-8. doi: 10.1016/j.cgh.2015.09.012. Epub 2015 Sep 24.
2
Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2016 Jan;14(1):166-7. doi: 10.1016/j.cgh.2015.04.022. Epub 2015 Apr 27.
3
Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2015 Feb;13(2):316-21. doi: 10.1016/j.cgh.2014.07.017. Epub 2014 Jul 17.
4
Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease-author's reply.
Aliment Pharmacol Ther. 2019 Sep;50(6):714-715. doi: 10.1111/apt.15457.
5
Risks and benefits of biologic therapy for inflammatory bowel diseases.
Gut. 2007 May;56(5):725-32. doi: 10.1136/gut.2006.103564.
6
Reply: To PMID 24703865.
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1577-8. doi: 10.1016/j.cgh.2014.04.029. Epub 2014 Apr 30.
7
Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2019 Sep;50(6):712-713. doi: 10.1111/apt.15411.
8
Venous thromboembolism risk in patients with inflammatory bowel disease: defining the benefits of pharmacologic prophylaxis.
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1577. doi: 10.1016/j.cgh.2014.03.025. Epub 2014 Apr 1.
9
The risks and benefits of early immunosuppression and biological therapy.
Dig Dis. 2012;30 Suppl 3:100-6. doi: 10.1159/000342731. Epub 2013 Jan 3.
10
Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.
Lancet. 2010 Feb 20;375(9715):657-63. doi: 10.1016/S0140-6736(09)61963-2. Epub 2010 Feb 8.
Zotero 插件